Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo

[1]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[2]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[3]  K. Kaneko,et al.  siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitro. , 2005, Biochemical and biophysical research communications.

[4]  Elena Cattaneo,et al.  Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.

[5]  I. Kanazawa,et al.  Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA , 2005, Neuroscience Research.

[6]  R. Mandel,et al.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  S. Batalov,et al.  Antisense Transcription in the Mammalian Transcriptome , 2005, Science.

[8]  S. Salzberg,et al.  The Transcriptional Landscape of the Mammalian Genome , 2005, Science.

[9]  Xiaoan Ruan,et al.  siRNA-mediated off-target gene silencing triggered by a 7 nt complementation , 2005, Nucleic acids research.

[10]  M. Hayden,et al.  Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.

[11]  H. Paulson,et al.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Steer,et al.  Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. , 2005, Biochemical and biophysical research communications.

[13]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[14]  S. Akira,et al.  Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.

[15]  B. Cullen,et al.  Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. , 2005, RNA.

[16]  H. Robertson,et al.  Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington′s disease transgenic mice prior to the onset of motor symptoms , 2004, Neuroscience.

[17]  D. Rubinsztein,et al.  Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease , 2004, The Journal of Neuroscience.

[18]  Aimee L Jackson,et al.  Noise amidst the silence: off-target effects of siRNAs? , 2004, Trends in genetics : TIG.

[19]  C. Steer,et al.  Double-stranded siRNA targeted to the huntingtin gene does not induce DNA methylation. , 2004, Biochemical and biophysical research communications.

[20]  R. Mandel,et al.  Clinical trials in neurological disorders using AAV vectors: promises and challenges. , 2004, Current opinion in molecular therapeutics.

[21]  John J Rossi,et al.  Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase , 2004, Nature Biotechnology.

[22]  Xiao-Jiang Li,et al.  Huntingtin-protein interactions and the pathogenesis of Huntington's disease. , 2004, Trends in genetics : TIG.

[23]  Ruth Luthi-Carter,et al.  Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice , 2003, The Journal of Neuroscience.

[24]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[25]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[26]  D. Rubinsztein,et al.  Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.

[27]  S. Hersch,et al.  Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease , 2002, The Journal of Neuroscience.

[28]  W. Hauswirth,et al.  Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. , 2002, Methods.

[29]  Ole A. Andreassen,et al.  Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease , 2002, The Journal of Neuroscience.

[30]  H. Robertson,et al.  Immediate‐early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice , 2002, Journal of neuroscience research.

[31]  C. Nellemann,et al.  Inhibition of Huntingtin Synthesis by Antisense Oligodeoxynucleotides , 2000, Molecular and Cellular Neuroscience.

[32]  L. Thompson,et al.  Antisense-mediated down-regulation of the human huntingtin gene. , 2000, The Journal of pharmacology and experimental therapeutics.

[33]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[34]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[35]  Ole A. Andreassen,et al.  Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease , 2000, The Journal of Neuroscience.

[36]  P. Greengard,et al.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C A Ross,et al.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.

[38]  M. Chesselet,et al.  Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.

[39]  K. Taira,et al.  Chemical and enzymatic probing of effector-mediated changes in the conformation of a maxizyme. , 2000, Journal of inorganic biochemistry.

[40]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[41]  R. Kalb,et al.  Sequence‐specific cleavage of Huntingtin mRNA by catalytic DNA , 1999, Annals of neurology.

[42]  B. Byrne,et al.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.

[43]  J. Penney,et al.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.

[44]  C. Ross,et al.  Expression of the Huntington's disease (IT15) protein product in HD patients. , 1995, Human molecular genetics.

[45]  Christopher A Ross,et al.  Widespread expression of Huntington's disease gene (IT15) protein product , 1995, Neuron.

[46]  G. Hammond,et al.  Tissue distribution of alpha 1-proteinase inhibitor messenger ribonucleic acid and its regulation by glucocorticoids in fetal and neonatal sheep. , 1993, Biology of reproduction.

[47]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[48]  J. Gauldie,et al.  Ontogeny and tissue distribution of alpha-1-antitrypsin of the mouse. , 1981, Biochimica et biophysica acta.